NASDAQ:IDXX IDEXX Laboratories - IDXX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding IDEXX Laboratories, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $480.50 -2.45 (-0.51%) (As of 01/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$477.36▼$486.2250-Day Range$399.93▼$496.1452-Week Range$317.06▼$574.33Volume555,650 shsAverage Volume563,639 shsMarket Capitalization$39.80 billionP/E Ratio61.05Dividend YieldN/APrice Target$485.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability IDEXX Laboratories MarketRank™ ForecastAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside0.9% Upside$485.00 Price TargetShort InterestN/ADividend StrengthN/ASustainability-2.80Upright™ Environmental ScoreNews Sentiment0.88Based on 12 Articles This WeekInsider TradingSelling Shares$12.54 M Sold Last QuarterProj. Earnings Growth19.14%From $7.89 to $9.40 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.10 out of 5 starsMedical Sector557th out of 1,055 stocksDiagnostic Substances Industry6th out of 17 stocks 1.4 Analyst's Opinion Consensus RatingIDEXX Laboratories has received a consensus rating of Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $485.00, IDEXX Laboratories has a forecasted upside of 0.9% from its current price of $480.50.Amount of Analyst CoverageIDEXX Laboratories has only been the subject of 3 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for IDXX. Previous Next 0.0 Dividend Strength Dividend YieldIDEXX Laboratories does not currently pay a dividend.Dividend GrowthIDEXX Laboratories does not have a long track record of dividend growth. Previous Next 2.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIDEXX Laboratories has received a 20.02% net impact score from Upright. Idexx Laboratories seems to create the most significant positive value in categories "Taxes", "Nutrition", and "Jobs". The positive contribution in the "Nutrition" impact category is mostly driven by its "Veterinary x-rays", "Veterinary hematology analyzers", and "Veterinary services for livestock" products. See details.Environmental SustainabilityThe Environmental Impact score for IDEXX Laboratories is -2.80. Previous Next 3.3 News and Social Media Coverage News SentimentIDEXX Laboratories has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for IDEXX Laboratories this week, compared to 4 articles on an average week.Search Interest13 people have searched for IDXX on MarketBeat in the last 30 days. This is an increase of 225% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added IDEXX Laboratories to their MarketBeat watchlist in the last 30 days. This is a decrease of -54% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IDEXX Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,541,681.00 in company stock.Percentage Held by InsidersOnly 2.06% of the stock of IDEXX Laboratories is held by insiders.Percentage Held by Institutions87.90% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for IDEXX Laboratories are expected to grow by 19.14% in the coming year, from $7.89 to $9.40 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IDEXX Laboratories is 61.05, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 141.04.Price to Earnings Ratio vs. SectorThe P/E ratio of IDEXX Laboratories is 61.05, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 157.95.Price to Earnings Growth RatioIDEXX Laboratories has a PEG Ratio of 2.99. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioIDEXX Laboratories has a P/B Ratio of 59.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About IDEXX Laboratories (NASDAQ:IDXX) StockIDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in WestRead More Receive IDXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter. Email Address IDXX Stock News HeadlinesJanuary 4, 2023 | marketbeat.comGE HealthCare Technologies Soars As GE Legacy Business Plummets (IDXX)Wednesday marked the trading debut of GE HealthCare Technologies, the health-focused business spun off from General Electric. Shares rose 12%.January 31, 2023 | marketwatch.comIDEXX Laboratories Inc. stock falls Tuesday, underperforms marketJanuary 31, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 31, 2023 | finance.yahoo.comSONVY or IDXX: Which Is the Better Value Stock Right Now?January 29, 2023 | americanbankingnews.comIDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives $473.13 Average PT from AnalystsJanuary 29, 2023 | americanbankingnews.comIDEXX Laboratories (NASDAQ:IDXX) Price Target Raised to $530.00 at The Goldman Sachs GroupJanuary 26, 2023 | finance.yahoo.comIDEXX Laboratories to Release 2022 Fourth Quarter and Full Year Financial ResultsJanuary 25, 2023 | finance.yahoo.comIdexx Laboratories (IDXX) Earnings Expected to Grow: What to Know Ahead of Q4 ReleaseJanuary 31, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 25, 2023 | finance.yahoo.comIDEXX Laboratories Is Barking Up the Right TreeJanuary 24, 2023 | marketwatch.comIDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitorsJanuary 18, 2023 | finance.yahoo.comHere's How Much You'd Have If You Invested $1000 in Idexx Laboratories a Decade AgoJanuary 12, 2023 | finance.yahoo.comDoes IDEXX Laboratories (NASDAQ:IDXX) Have A Healthy Balance Sheet?January 9, 2023 | finance.yahoo.comIDEXX Laboratories Stock Clears Technical Benchmark, Hitting 80-Plus RS RatingJanuary 8, 2023 | finance.yahoo.comIDEXX Laboratories, Inc. (NASDAQ:IDXX) insiders made a handsome profit after selling stock presently valued at US$448 apiece for US$510January 4, 2023 | finance.yahoo.comIs It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?December 27, 2022 | msn.comGolden Cross Appears Before IDEXX Laboratories InvestorsDecember 22, 2022 | finance.yahoo.comIDEXX Laboratories to Present at the Goldman Sachs Healthcare CEOs Unscripted ConferenceDecember 15, 2022 | marketwatch.comIDEXX Laboratories Inc. stock falls Thursday, underperforms marketDecember 14, 2022 | marketwatch.comIDEXX Laboratories Inc. stock falls Wednesday, underperforms marketDecember 12, 2022 | finance.yahoo.comIDEXX Laboratories (NASDAQ:IDXX) shareholders have earned a 22% CAGR over the last five yearsDecember 7, 2022 | finance.yahoo.com11 Best Pet Stocks To Buy NowDecember 5, 2022 | seekingalpha.comIDEXX Laboratories: Not Enough Visibility, HoldNovember 17, 2022 | benzinga.comMassive Insider Trade At IDEXX LaboratoriesNovember 15, 2022 | msn.comMorgan Stanley Maintains Overweight Rating for IDEXX Laboratories: Here's What You Need To KnowNovember 15, 2022 | forbes.comIs There More Room For Growth In IDEXX Laboratories Stock?November 10, 2022 | benzinga.comIDEXX Laboratories President & CEO Trades Company's StockSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IDXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter. Email Address IDXX Company Calendar Last Earnings11/02/2021Today1/31/2023Next Earnings (Confirmed)2/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:IDXX CUSIP45168D10 CIK874716 Webwww.idexx.com Phone(207) 556-0300Fax207-556-4346Employees10,350Year Founded1983Price Target and Rating Average Stock Price Forecast$485.00 High Stock Price Forecast$582.00 Low Stock Price Forecast$415.00 Forecasted Upside/Downside+0.9%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$7.87 Trailing P/E Ratio61.05 Forward P/E Ratio60.90 P/E Growth2.99Net Income$744.84 million Net Margins20.05% Pretax Margin25.11% Return on Equity118.38% Return on Assets26.06% Debt Debt-to-Equity Ratio1.60 Current Ratio0.89 Quick Ratio0.59 Sales & Book Value Annual Sales$3.22 billion Price / Sales12.38 Cash Flow$9.88 per share Price / Cash Flow48.61 Book Value$8.14 per share Price / Book59.03Miscellaneous Outstanding Shares82,820,000Free Float81,111,000Market Cap$39.80 billion OptionableOptionable Beta1.18 Social Links Key ExecutivesJonathan J. MazelskyPresident, Chief Executive Officer & DirectorBrian Patrick McKeonChief Financial Officer, Treasurer & Executive VPKen GradyChief Information Officer & Senior VPMurthy YerramilliSenior Vice President-Research & DevelopmentMartin Alexander SmithChief Technology Officer & Executive VPKey CompetitorsDexComNASDAQ:DXCMBiogenNASDAQ:BIIBCenteneNYSE:CNCHaleonNYSE:HLNAlconNYSE:ALCView All CompetitorsInsiders & InstitutionsBell BankSold 31 shares on 1/31/2023Ownership: 0.004%Wedbush Securities Inc.Sold 109 shares on 1/31/2023Ownership: 0.003%Geneos Wealth Management Inc.Bought 37 shares on 1/31/2023Ownership: 0.002%Balentine LLCBought 195 shares on 1/31/2023Ownership: 0.002%Seneca House AdvisorsSold 74 shares on 1/31/2023Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions IDXX Stock - Frequently Asked Questions Should I buy or sell IDEXX Laboratories stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IDXX shares. View IDXX analyst ratings or view top-rated stocks. What is IDEXX Laboratories' stock price forecast for 2023? 9 brokerages have issued twelve-month target prices for IDEXX Laboratories' shares. Their IDXX share price forecasts range from $415.00 to $582.00. On average, they expect the company's stock price to reach $485.00 in the next year. This suggests a possible upside of 0.9% from the stock's current price. View analysts price targets for IDXX or view top-rated stocks among Wall Street analysts. How have IDXX shares performed in 2023? IDEXX Laboratories' stock was trading at $407.96 at the beginning of 2023. Since then, IDXX stock has increased by 17.8% and is now trading at $480.50. View the best growth stocks for 2023 here. When is IDEXX Laboratories' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 6th 2023. View our IDXX earnings forecast. How can I listen to IDEXX Laboratories' earnings call? IDEXX Laboratories will be holding an earnings conference call on Monday, February 6th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were IDEXX Laboratories' earnings last quarter? IDEXX Laboratories, Inc. (NASDAQ:IDXX) released its quarterly earnings results on Tuesday, November, 2nd. The company reported $2.03 EPS for the quarter, beating analysts' consensus estimates of $1.88 by $0.15. The firm had revenue of $810.42 million for the quarter, compared to analyst estimates of $793.26 million. IDEXX Laboratories had a trailing twelve-month return on equity of 118.38% and a net margin of 20.05%. During the same quarter last year, the business earned $1.69 EPS. Read the conference call transcript. What guidance has IDEXX Laboratories issued on next quarter's earnings? IDEXX Laboratories issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided EPS guidance of $7.74-$7.98 for the period, compared to the consensus estimate of $7.95. The company issued revenue guidance of $3.33 billion-$3.37 billion, compared to the consensus revenue estimate of $3.37 billion. What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO? 40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among the company's employees. What other stocks do shareholders of IDEXX Laboratories own? Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Block (SQ), Walt Disney (DIS) and Shopify (SHOP). What is IDEXX Laboratories' stock symbol? IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX." Who are IDEXX Laboratories' major shareholders? IDEXX Laboratories' stock is owned by a number of institutional and retail investors. Top institutional investors include LGT Capital Partners LTD. (0.38%), UMB Bank n.a. (0.34%), Sumitomo Mitsui Trust Holdings Inc. (0.30%), Manning & Napier Group LLC (0.21%), Bank Julius Baer & Co. Ltd Zurich (0.20%) and Riverbridge Partners LLC (0.15%). Insiders that own company stock include Brian P Mckeon, Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek. View institutional ownership trends. How do I buy shares of IDEXX Laboratories? Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is IDEXX Laboratories' stock price today? One share of IDXX stock can currently be purchased for approximately $480.50. How much money does IDEXX Laboratories make? IDEXX Laboratories (NASDAQ:IDXX) has a market capitalization of $39.80 billion and generates $3.22 billion in revenue each year. The company earns $744.84 million in net income (profit) each year or $7.87 on an earnings per share basis. How many employees does IDEXX Laboratories have? The company employs 10,350 workers across the globe. How can I contact IDEXX Laboratories? IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The official website for the company is www.idexx.com. The company can be reached via phone at (207) 556-0300, via email at investorrelations@idexx.com, or via fax at 207-556-4346. This page (NASDAQ:IDXX) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.